How to audit a peptide merchant statement
- Your real cost is the effective rate — total fees divided by total volume — not the rate on the contract.
- Peptide statements hide cost in padded interchange, monthly junk fees, and reserve lines most operators never read.
- Audit every statement the same way each month so a quiet mid-year rate creep does not cost you thousands.
On this page
A peptide operator forwarded us a statement last month and asked one question: "Am I getting screwed?" His contract said 3.9% plus a dime. His statement, once we did the division, said he was paying 5.2%. The gap was not fraud. It was a stack of small lines he had never read — a padded interchange tier, a monthly "PCI compliance" fee, a per-batch charge, a cross-border assessment on orders he did not realize were international, and a reserve hold he had mentally written off as gone. None of it was hidden, exactly. It was just buried in three pages of acronyms nobody taught him to read.
This is how you read those three pages. Do it once carefully and you will do it in ten minutes every month after.
Start at the bottom: find your effective rate
Before you read a single line item, do one division. Take total fees charged for the month and divide by total processing volume for the month. That number is your effective rate, and it is the only cost number that matters. The headline rate on your contract is a marketing number. The effective rate is what you actually paid.
For a peptide store on a specialist ISO, a healthy effective rate runs 3.5% to 4.5%. If your division comes back at 5% or higher and you are not on a parent-account orchestration model, something on the statement is padding. If it comes back under 3.5% on a peptide book, double-check you are reading total fees and not just the discount line — peptide processing does not come that cheap, and a suspiciously low number usually means a reserve hold or assessment line is sitting somewhere you have not looked yet.
Understand the three fee buckets
Every merchant statement, peptide or not, splits into three buckets. Knowing which bucket a fee lives in tells you whether it is negotiable.
- Interchange. Paid to the card-issuing bank. Non-negotiable, set by the networks, typically 1.65% to 2.60% plus about $0.10 on a card-not-present credit transaction. Nobody marks this down because nobody can.
- Assessments. Paid to Visa and Mastercard themselves. Also non-negotiable. Small per-transaction and per-volume charges, plus things like the cross-border assessment.
- Processor markup. Everything your ISO adds on top. This is the only bucket you can negotiate, and it is where padding hides.
An honest statement shows you interchange-plus pricing, where interchange and assessments pass through at cost and the markup sits on its own clearly labeled line. A tiered or "qualified/non-qualified" statement deliberately blends the buckets so you cannot see the markup. If your peptide processor uses tiered pricing, that is finding number one — ask for interchange-plus and re-audit.
Hunt the junk fees
The markup bucket is where the slow bleed lives. These are the lines that quietly add 50 to 150 basis points to a peptide book without anyone noticing:
| Line item | Typical charge | Negotiable? | What to ask |
|---|---|---|---|
| Monthly PCI fee | $10-$40/mo | Often | Why, if you self-attest compliance? |
| PCI non-compliance fee | $20-$50/mo | Yes | Complete the self-assessment to remove it |
| Statement / account fee | $10-$25/mo | Sometimes | Waiver at volume |
| Batch / settlement fee | $0.10-$0.25/batch | Sometimes | Batch once daily, not per order |
| Gateway fee | $15-$30/mo + per-txn | Sometimes | Bundled or separate? |
| Cross-border assessment | ~0.6-1.0% | No | Are these orders really international? |
None of these are scandalous on their own. Together, on a peptide store doing $80k a month, a stack of them is the difference between a 4.0% and a 4.9% effective rate — roughly $700 a month, $8,400 a year, for lines you never read.
Check your interchange tier, not just the markup
Here is the subtle one. Some processors quote a fair markup and then make their money on interchange downgrades. A transaction "downgrades" to a more expensive interchange tier when data is missing — no AVS, late settlement, missing order detail. On a clean statement, most of your volume should clear at the lowest applicable tier. If a large share is downgrading, you are leaving money on the table and the fix is operational: enable AVS, settle batches within 24 hours, pass complete transaction data. Re-audit the next month to confirm the downgrades dropped.
Read the reserve lines carefully
Peptide books almost always carry a rolling reserve — commonly 10% to 15% held for 180 days in year one. On your statement this shows as money withheld, not money spent, and the distinction matters. A reserve is your cash; it is coming back on a schedule. A fee is gone.
Audit three things on the reserve line. First, confirm the percentage matches your contract — reserve creep happens quietly after a rough chargeback month. Second, confirm releases are actually happening on schedule; money held past its release date is a cash-flow problem you can raise immediately. Third, total your held reserve across all months and make sure you are tracking it as a receivable, not writing it off. We see operators forget they are owed five figures. Read more on how reserve structures differ before you accept a renegotiation.
Reconcile volume against your own numbers
The statement says you processed a number. Your own order system says you sold a number. They should match within the gap of refunds and voids. If they do not, find out why before you do anything else — a mismatch means orders are clearing on a processor you forgot about, refunds are not posting, or fees are being charged on phantom volume. For multi-brand peptide operators this is where a single consolidated ledger earns its keep: reconciling five separate statements against five separate order systems by hand is exactly where errors hide.
When the audit says "restructure," not "renegotiate"
Sometimes the audit is not telling you to call your ISO and argue about a $25 statement fee. Sometimes it is telling you the whole structure is wrong. If you are running three or more peptide brands on three or more separate merchant accounts, you are auditing three or more separate statements, paying three or more sets of monthly junk fees, and carrying three or more reserves. Consolidating onto a parent merchant account collapses that into one statement, one reserve to track, and one effective rate to manage.
That is the model we orchestrate for multi-brand peptide operators — we sit on top of your acquirer and gateway, not in place of them, so the consolidated ledger and the per-brand descriptors live in one place. We charge 5.5% to 7.5% per transaction plus setup, which only beats specialist-ISO pricing once you are running enough brands that the multi-statement overhead is the real cost. For a single brand, a clean interchange-plus audit at your current ISO beats us every time, and we will say so. Compare the two paths in our Authorize.net breakdown.
If your audit turned up an effective rate you cannot explain across several brands, an honest fit check is twelve questions and gets you a straight read on whether consolidation actually lowers your total cost or just moves it around. If you are single-brand, keep the audit, fix the junk fees, and pocket the difference.